Savitch I, Kew M C, Paterson A, Esser J D, Levin J
J Nucl Med. 1983 Dec;24(12):1119-22.
Uptake of Tc-99m di-isopropyliminodiacetic acid (DISIDA) by hepatocellular carcinoma was assessed in 30 patients showing obvious liver defects on a Tc-99m tin colloid image. In none of these patients was there complete "filling in" of the defects, and even partial "filling in" occurred in only 11 (36.7%). There was no uptake of Tc-99m DISIDA by the primary tumor in the remaining 19 patients (63.3%). In 19 of the 30 patients an attempt was made to correlate the degree of histologic differentiation of the tumor with the uptake of DISIDA by the tumor. No difference in uptake could be demonstrated between well, moderately, and poorly differentiated tumors. Tc-99m DISIDA was not taken up by pulmonary metastases in the only two patients tested. We conclude that imaging with Tc-99m DISIDA in conjunction with Tc-99m colloid is of no value in the specific diagnosis of hepatocellular carcinoma.
在30例Tc-99m胶体显像显示肝脏有明显缺损的患者中,评估了肝细胞癌对Tc-99m二异丙基亚氨基二乙酸(DISIDA)的摄取情况。这些患者中无一例缺损完全“填充”,仅有11例(36.7%)出现部分“填充”。其余19例患者(63.3%)的原发性肿瘤未摄取Tc-99m DISIDA。在30例患者中的19例中,尝试将肿瘤的组织学分化程度与肿瘤对DISIDA的摄取进行关联。高分化、中分化和低分化肿瘤之间在摄取方面未显示出差异。仅有的2例接受检测的患者中,肺转移灶未摄取Tc-99m DISIDA。我们得出结论,Tc-99m DISIDA与Tc-99m胶体联合显像对肝细胞癌的特异性诊断无价值。